Abstract

Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF. Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.

Original languageEnglish
Pages (from-to)5
Number of pages1
JournalCell
Volume173
Issue number1
DOIs
StatePublished - Mar 22 2018

Fingerprint

Dive into the research topics of 'Gene Therapy for Retinal Degeneration'. Together they form a unique fingerprint.

Cite this